AU2011278096B2 - Pharmaceutical compositions comprising R (+) budesonide and one or more bronchodilators - Google Patents

Pharmaceutical compositions comprising R (+) budesonide and one or more bronchodilators Download PDF

Info

Publication number
AU2011278096B2
AU2011278096B2 AU2011278096A AU2011278096A AU2011278096B2 AU 2011278096 B2 AU2011278096 B2 AU 2011278096B2 AU 2011278096 A AU2011278096 A AU 2011278096A AU 2011278096 A AU2011278096 A AU 2011278096A AU 2011278096 B2 AU2011278096 B2 AU 2011278096B2
Authority
AU
Australia
Prior art keywords
budesonide
pharmaceutical composition
composition according
tiotropium
beta
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2011278096A
Other languages
English (en)
Other versions
AU2011278096A1 (en
Inventor
Amar Lulla
Geena Malhotra
Shrinivas Madhukar Purandare
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cipla Ltd
Original Assignee
Cipla Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cipla Ltd filed Critical Cipla Ltd
Publication of AU2011278096A1 publication Critical patent/AU2011278096A1/en
Application granted granted Critical
Publication of AU2011278096B2 publication Critical patent/AU2011278096B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2011278096A 2010-07-16 2011-07-18 Pharmaceutical compositions comprising R (+) budesonide and one or more bronchodilators Active AU2011278096B2 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
IN2051MU2010 2010-07-16
IN2051/MUM/2010 2010-07-16
IN3156MU2010 2010-11-18
IN3157/MUM/2010 2010-11-18
IN3157MU2010 2010-11-18
IN3156/MUM/2010 2010-11-18
PCT/GB2011/001077 WO2012007729A2 (en) 2010-07-16 2011-07-18 Pharmaceutical compositions

Publications (2)

Publication Number Publication Date
AU2011278096A1 AU2011278096A1 (en) 2013-02-14
AU2011278096B2 true AU2011278096B2 (en) 2014-08-28

Family

ID=44629226

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2011278096A Active AU2011278096B2 (en) 2010-07-16 2011-07-18 Pharmaceutical compositions comprising R (+) budesonide and one or more bronchodilators

Country Status (13)

Country Link
US (4) US20130274232A1 (cg-RX-API-DMAC10.html)
EP (2) EP3871676A1 (cg-RX-API-DMAC10.html)
JP (3) JP2013531056A (cg-RX-API-DMAC10.html)
KR (2) KR20140020815A (cg-RX-API-DMAC10.html)
CN (3) CN105412122A (cg-RX-API-DMAC10.html)
AU (1) AU2011278096B2 (cg-RX-API-DMAC10.html)
BR (1) BR112013001119A2 (cg-RX-API-DMAC10.html)
CA (1) CA2805700A1 (cg-RX-API-DMAC10.html)
MX (1) MX2013000642A (cg-RX-API-DMAC10.html)
NZ (1) NZ605920A (cg-RX-API-DMAC10.html)
RU (1) RU2568882C2 (cg-RX-API-DMAC10.html)
WO (1) WO2012007729A2 (cg-RX-API-DMAC10.html)
ZA (1) ZA201300718B (cg-RX-API-DMAC10.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12472190B2 (en) 2010-07-16 2025-11-18 Cipla Limited Pharmaceutical compositions

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2885767A1 (en) * 2012-10-23 2014-05-01 Cipla Limited Pharmaceutical composition
WO2015018800A1 (en) * 2013-08-05 2015-02-12 Chemo Research, S.L. Inhalable particles comprising tiotropium and indacaterol
CN104744271B (zh) * 2013-12-26 2016-08-31 成都伊诺达博医药科技有限公司 一种合成维兰特罗的新工艺
GB201408387D0 (en) * 2014-05-12 2014-06-25 Teva Pharmaceuticals Europ B V Treatment of respiratory disorders
US20170189329A1 (en) 2014-07-29 2017-07-06 3M Innovative Properties Company Method of preparing a pharmaceutical composition
CN104606205A (zh) * 2015-01-13 2015-05-13 段希福 一种奥达特罗和布地奈德的药物组合物及其用途
CN112472689B (zh) * 2015-12-04 2023-01-17 墨西哥氟石股份公司 药物组合物
CN106466322A (zh) * 2016-08-25 2017-03-01 杭州百诚医药科技股份有限公司 一种以布地奈德和噻托溴铵为活性成分的复方制剂
WO2019142214A1 (en) * 2018-01-19 2019-07-25 Cipla Limited Pharmaceutical composition comprising tiotropium for inhalation
WO2019236559A1 (en) * 2018-06-04 2019-12-12 Lupin Inc. Stable pharmaceutical compositions for pressurized metered dose inhalers
WO2020141472A1 (en) * 2019-01-03 2020-07-09 Glenmark Specialty S.A. Nebulization composition comprising tiotropium and indacaterol
CN110051629A (zh) * 2019-05-17 2019-07-26 南京望知星医药科技有限公司 一种用于治疗呼吸疾病的雾化沙丁胺醇溶液及其制备方法
GB202001537D0 (en) * 2020-02-05 2020-03-18 Consort Medical Plc Pressurised dispensing container
CN111481550A (zh) * 2020-05-14 2020-08-04 王兆霖 含有噻托溴铵和阿福特罗的药物制剂
WO2021262675A1 (en) * 2020-06-23 2021-12-30 Anovent Pharmaceutical (U.S.), Llc Preparation of a pharmaceutical composition of olodaterol, tiotropium bromide and budesonide
EP4221707A4 (en) 2020-09-29 2024-08-28 Aerorx Therapeutics LLC Liquid formulations of indacaterol
US20240156734A1 (en) * 2022-11-11 2024-05-16 Michael Farber Simplified Method for Making Shelf Stable Highly Water Soluble Anhydrous Compositions Of Cyclodextrin Complexes of Macrocyclic Lactones
WO2026047392A1 (en) * 2024-08-26 2026-03-05 Glenmark Specialty S.A. A pressurized inhalation composition of tiotropium

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999064014A1 (en) * 1998-06-11 1999-12-16 Astrazeneca Ab Use of a composition comprising formoterol and budesonide for the prevention or treatment of an acute condition of asthma
WO2003063842A1 (en) * 2002-02-01 2003-08-07 Astrazeneca Ab Composition for inhalation
WO2003074025A2 (en) * 2002-03-01 2003-09-12 Chiesi Farmaceutici S.P.A. Pressurised metered dose inhalers containing solutions of beta-2 agonists
EP1452179A1 (en) * 2003-02-27 2004-09-01 CHIESI FARMACEUTICI S.p.A. Novel medicament combination of a highly potent long-lasting beta2-agonist and a corticosteroid
CN101249093A (zh) * 2008-03-19 2008-08-27 李虎山 一种治疗慢性阻塞性肺部疾病的组合物

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DZ2947A1 (fr) * 1998-11-25 2004-03-15 Chiesi Farma Spa Inhalateur à compteur de dose sous pression.
SE9900834D0 (sv) * 1999-03-09 1999-03-09 Astra Ab Novel combination
GB0009584D0 (en) * 2000-04-18 2000-06-07 Glaxo Group Ltd Pharmaceutical compositions
GB0009613D0 (en) 2000-04-18 2000-06-07 Glaxo Group Ltd Pharmaceutical compositions
GB0009583D0 (en) * 2000-04-18 2000-06-07 Glaxo Group Ltd Respiratory formulations
IT1318514B1 (it) 2000-05-12 2003-08-27 Chiesi Farma Spa Formulazioni contenenti un farmaco glucocorticosteroide per iltrattamento di patologie broncopolmonari.
US20060257324A1 (en) * 2000-05-22 2006-11-16 Chiesi Farmaceutici S.P.A. Pharmaceutical solution formulations for pressurised metered dose inhalers
GB0029562D0 (en) * 2000-12-04 2001-01-17 Novartis Ag Organic compounds
DE10130371A1 (de) 2001-06-23 2003-01-02 Boehringer Ingelheim Pharma Neue Arzneimittelkompositionen auf der Basis von Anticholinergika, Corticosteroiden und Betamimetika
DE60202299T2 (de) * 2001-08-07 2005-12-08 Galephar M/F Pharmazeutische zusammensetzung enthaltend salmeterol und budesonid zur behandlung von atemkrankheiten
JPWO2003041717A1 (ja) 2001-11-12 2005-03-03 小野薬品工業株式会社 プロスタグランジン誘導体を有効成分とする局所投与用持続性フィルム状製剤
KR20030065831A (ko) 2002-02-01 2003-08-09 주식회사 태평양 사이클로스포린을 함유한 지속 방출형 약학적 조성물
EP1415647A1 (en) 2002-10-23 2004-05-06 CHIESI FARMACEUTICI S.p.A. "Long-acting beta-2 agonists ultrafine formulations"
EP1531866A1 (en) * 2002-08-29 2005-05-25 Cipla Ltd. Pharmaceutical products and compositions comprising specific anticholinergic agents, beta-2 agonists and corticosteroids
AU2003263717A1 (en) 2002-09-25 2004-04-19 Astrazeneca Ab A COMBINATION OF A LONG-ACTING Beta2-AGONIST AND A GLUCOCORTICOSTEROID IN THE TREATMENT OF FIBROTIC DISEASES
US6840529B2 (en) * 2002-10-17 2005-01-11 David B. Call Articulated pickup truck camper/trailer
US7550133B2 (en) * 2002-11-26 2009-06-23 Alexza Pharmaceuticals, Inc. Respiratory drug condensation aerosols and methods of making and using them
DE10256080A1 (de) * 2002-11-29 2004-06-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Tiotropiumhaltige Arzneimittelkombination für die Inhalation
US7250426B2 (en) * 2002-11-29 2007-07-31 Boehringer Ingelheim Pharma Gmbh & Co Kg Tiotropium-containing pharmaceutical combination for inhalation
SE527190C2 (sv) 2003-06-19 2006-01-17 Microdrug Ag Inhalatoranordning samt kombinerade doser av en beta2-agonist, ett antikolinergiskt medel och ett antiinflammatorisk steroid
TWI359675B (en) * 2003-07-10 2012-03-11 Dey L P Bronchodilating β-agonist compositions
US20070020299A1 (en) 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
US20070020298A1 (en) 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether gamma-cyclodextrin and corticosteroid
ATE497787T1 (de) 2004-03-12 2011-02-15 Cipla Ltd Sterilisationsprozess für steroide
GB0415789D0 (en) 2004-07-15 2004-08-18 Astrazeneca Ab Novel combination
RU2440972C2 (ru) 2004-12-17 2012-01-27 Сипла Лимитед Кристаллический сульфат левосальбутамола, способ его получения и фармацевтическая композиция, содержащая его
JP5281291B2 (ja) * 2005-01-10 2013-09-04 グラクソ グループ リミテッド 新規化合物
EP2484382A1 (en) 2005-03-30 2012-08-08 Schering Corporation Medicament comprising a phosphodiesterase IV inhibitor in an inhalable form
EP2124915A2 (en) 2007-02-19 2009-12-02 Cipla Limited Pharmaceutical combinations of at least two bronchodilators or of a bronchodilator with a corticosteroid
EP2011534A1 (en) * 2007-07-03 2009-01-07 CHIESI FARMACEUTICI S.p.A. Metered dose inhaler actuator
MX2013000642A (es) 2010-07-16 2013-04-03 Cipla Ltd Composiciones farmaceuticas.
KR20180028563A (ko) 2010-10-12 2018-03-16 시플라 리미티드 약학 조성물
RU2678992C2 (ru) 2012-04-11 2019-02-05 Сипла Лимитед Фармацевтическая композиция, содержащая арформотерол и флутиказона фуроат
US9913853B2 (en) 2015-11-03 2018-03-13 Cipla Limited Stabilized liquid fosaprepitant formulations

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999064014A1 (en) * 1998-06-11 1999-12-16 Astrazeneca Ab Use of a composition comprising formoterol and budesonide for the prevention or treatment of an acute condition of asthma
WO2003063842A1 (en) * 2002-02-01 2003-08-07 Astrazeneca Ab Composition for inhalation
WO2003074025A2 (en) * 2002-03-01 2003-09-12 Chiesi Farmaceutici S.P.A. Pressurised metered dose inhalers containing solutions of beta-2 agonists
EP1452179A1 (en) * 2003-02-27 2004-09-01 CHIESI FARMACEUTICI S.p.A. Novel medicament combination of a highly potent long-lasting beta2-agonist and a corticosteroid
CN101249093A (zh) * 2008-03-19 2008-08-27 李虎山 一种治疗慢性阻塞性肺部疾病的组合物

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12472190B2 (en) 2010-07-16 2025-11-18 Cipla Limited Pharmaceutical compositions

Also Published As

Publication number Publication date
CN110237260A (zh) 2019-09-17
WO2012007729A3 (en) 2012-05-31
US20130274232A1 (en) 2013-10-17
RU2568882C2 (ru) 2015-11-20
US20170333452A1 (en) 2017-11-23
KR20180091120A (ko) 2018-08-14
US11077124B2 (en) 2021-08-03
JP2018199684A (ja) 2018-12-20
EP2593108A2 (en) 2013-05-22
JP2017039736A (ja) 2017-02-23
CN103096897A (zh) 2013-05-08
JP2013531056A (ja) 2013-08-01
NZ605920A (en) 2015-01-30
US20130330281A1 (en) 2013-12-12
US20210308150A1 (en) 2021-10-07
KR20140020815A (ko) 2014-02-19
MX2013000642A (es) 2013-04-03
WO2012007729A2 (en) 2012-01-19
ZA201300718B (en) 2013-08-28
US12472190B2 (en) 2025-11-18
RU2013106866A (ru) 2014-08-27
BR112013001119A2 (pt) 2016-05-24
AU2011278096A1 (en) 2013-02-14
CA2805700A1 (en) 2012-01-19
CN105412122A (zh) 2016-03-23
EP3871676A1 (en) 2021-09-01

Similar Documents

Publication Publication Date Title
US12472190B2 (en) Pharmaceutical compositions
AU2011315315B2 (en) Pharmaceutical composition
AU2012216890A1 (en) Combination of glycopyrrolate and a beta2 -agonist
WO2014016548A2 (en) Pharmaceutical composition
AU2017276321A1 (en) Pharmaceutical composition comprising arformoterol and fluticasone furoate
WO2012010854A1 (en) Inhalation formulations comprising carmoterol in combination with a corticosteroid
NZ613915B2 (en) Combination of glycopyrrolate, fluticasone and indacaterol

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)